SMAD4 and gastric cancer: Statistically, the SMAD4 nuclear loss group tended to be associated with a worse survival rate compared with the SMAD4 preservation group among EBV-positive stomach cancer patients, but not statistically significant (P = 0.08), and SMAD4 showed no prognostic implication among EBV-negative stomach cancer patients (Table 2 and Figure 6).